Collaborations, Competitor News

EVERSANA and UpScriptHealth Announce Integrated, Direct-to-Patient Platform, Transforming the Patient Journey to Accelerate Therapy Access, Affordability and Adherence

Posted on

CHICAGO and SCOTTSDALE, Ariz., April 14, 2022 /PRNewswire/ — EVERSANA™, the pioneer of next-generation commercial services to the global life sciences industry, and UpScriptHealth™, the leading telehealth and virtual prescribing platform serving life sciences companies, today announced a strategic partnership to create a direct-to-patient platform that will transform the patient experience to help accelerate access to therapies…

Collaborations, Competitor News, Data Partnership, Oncology

Existing Data may help Identify Ancestry-associated Features Across Multiple Cancer Types

Posted on

People with different ancestries inherit different risks and encounter different environmental exposures resulting in different somatic profiles. Research Presented at the American Association for Cancer Research (AACR) Annual Meeting, held April 8-13, 2022 in New Orleans, Louisiana, demonstrates that a lack of knowledge about ancestry-specific alterations is a major barrier…

AI, Europe, Government/Regulatory, Industry News, International

Help shape our evidence standards framework for digital and artificial intelligence health and care technologies

Posted on

Harriet Unsworth outlines her role in updating our evidence standards framework for digital health technologies. She also explains how you can share your views as part of our consultation. 12 April 2022 Harriet Unsworth, NICE technical adviser for digital health. Care models are changing all around us. The significant advancement…

Collaborations, Competitor News, Oncology

Texas Oncology Announces Collaboration to Provide More Cancer Patients with Access to Liquid Biopsy Testing from Foundation Medicine

Posted on

April 13, 2022 09:50 AM Eastern Daylight Time DALLAS–(BUSINESS WIRE)–Texas Oncology announced today that it has entered into an agreement with Foundation Medicine, a pioneer in molecular profiling for cancer, to provide Texas Oncology care teams with access to its Food and Drug Administration (FDA)-approved blood-based comprehensive genomic profiling (CGP)…

Collaborations, Competitor News, Data Partnership, Pharma

Mallinckrodt Announces Publication of Real-World Data from Retrospective Study on the Investigational Use of Inhaled Nitric Oxide in Hospitalized COVID-19 Patients

Posted on

– Medical chart review study, published in Drugs in Context, evaluated the real-world use of INOmax® (nitric oxide) gas, for inhalation in hospitalized COVID-19 patients with mild-to-moderate acute respiratory distress syndrome (ARDS) in the U.S. – DUBLIN, April 13, 2022 /PRNewswire/ — Mallinckrodt plc (OTCMKTS:MNKKQ), a global biopharmaceutical company, today announced the publication of findings from a retrospective…

Industry News, RWE Study

Real-World Analysis of THP in mBC Shows Similar Survival, Safety Outcomes to CLEOPATRA Trial

Posted on

Pertuzumab combined with trastuzumab, and docetaxel revealed comparable survival outcomes with previous studies of patients with metastatic breast cancer, including the CLEOPATRA trial. A real-world analysis evaluating the triplet regimen of pertuzumab (Perjeta), trastuzumab (Herceptin), and docetaxel—THP—in Korean patients with metastatic breast cancer (mBC) revealed comparable survival outcomes with previous…

Industry News, RWE Study

Real World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients

Posted on

ABSTRACT BACKGROUND: It is not known whether sotrovimab, a neutralizing monoclonal antibody (mAb) treatment authorized for early symptomatic COVID-19 patients, is effective against the SARS-CoV-2 Delta variant to prevent progression to severe disease and mortality. METHODS: Observational cohort study of non-hospitalized adult patients with SARS-CoV-2 infection from October 1 st 2021 –…